Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

NCT05965167 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoparathyroidism
Osteoporosis
Fractures, Bone
Other Disease

Interventions

DRUG: EBP05
DRUG: Forteo 0.02 mg
DRUG: EBP11
DRUG: EBP22
DRUG: EBP11-F2
DRUG: EBP11-F4
DRUG: EBP11-F1
DRUG: EBP11-F5

Sponsor

Entera Bio Ltd.